Welcome to our dedicated page for Scinai Immunotherapeutics news (Ticker: SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics stock.
Scinai Immunotherapeutics Ltd. reports developments as a Nasdaq-listed biopharmaceutical issuer with American Depositary Shares and a dual model spanning inflammation and immunology R&D and contract development and manufacturing services. Its updates cover the PC111 monoclonal antibody program targeting soluble Fas Ligand for severe dermatological and autoimmune conditions, next-generation NanoAb-based programs, and development rights or research funding tied to its immunology pipeline.
Company news also covers the CDMO platform operated through Scinai Biopharma Services Ltd., including the completed acquisition of Recipharm Israel, manufacturing capabilities across biologics and small-molecule programs, customer service expansion, operating results, material agreements, shareholder matters, capital-structure disclosures, and Nasdaq listing compliance for its ADSs.
Scinai Immunotherapeutics (NASDAQ: SCNI) will lead a strategic roundtable at the 7th Dermatology Drug Development Summit Europe in Amsterdam.
The session, led by CEO Amir Reichman and Dr. Meital Portugal, will examine how oral peptides and small molecules may complement or compete with biologic therapies in immunology and dermatology.
Scinai (NASDAQ: SCNI) announced a private placement and warrant inducement expected to close on or about April 27, 2026, raising approximately $2.61 million gross before fees and expenses. The financing includes 5,208,333 ADSs at $0.48 per ADS and two warrant series exercisable at $0.48 and $0.55.
The company said net proceeds will support expansion of its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. A.G.P./Alliance Global Partners served as sole financial advisor.
Scinai (NASDAQ: SCNI) completed a strategic reorganization on April 6, 2026, creating a dedicated CDMO subsidiary, Scinai Biopharma Services, following its February 2026 acquisition of Recipharm Israel (Yavne site). The move separates CDMO operations from a leaner R&D-focused Scinai Immunotherapeutics and targets ~$5 million in CDMO revenues for 2026.
The CDMO platform combines Jerusalem biologics capabilities, Yavne small-molecule/API capacity, and a commercial collaboration with Recipharm that provides subcontracting access and referral-based royalties.
Scinai (NASDAQ: SCNI) reported full-year 2025 results with CDMO revenues doubling to $1.3 million and a year-end cash position of $1.8 million. Net loss was $8.3 million, driven in part by the absence of 2024 financial income. Post‑year-end, Scinai acquired Recipharm Israel and signed a strategic collaboration to expand CDMO capabilities into small‑molecule manufacturing. The company resubmitted a FENG grant request that could provide up to €12 million in funding matched by ~€3 million company investment.
Scinai Immunotherapeutics (Nasdaq: SCNI) will attend BIO-Europe Spring 2026 in Lisbon March 23–25, showcasing its expanded CDMO platform and antibody-based immunology pipeline following the acquisition of Recipharm Israel and a strategic collaboration with Recipharm.
Highlights: integrated cGMP biologics site in Jerusalem, acquired cGMP small-molecule API site in Yavne, a client "graduation" model from early development to commercial supply, and a dermatology-focused antibody pipeline licensed from Max Planck, University Medical Center Göttingen, and PinCell.
Scinai Immunotherapeutics (Nasdaq: SCNI) said it received a Nasdaq written notice dated March 12, 2026, for noncompliance with the Nasdaq Capital Market minimum $1.00 bid price rule after ADSs closed below $1.00 for 30 consecutive business days.
The notice does not affect current listing or trading and provides an initial 180-calendar-day compliance period through September 8, 2026 to regain the $1.00 minimum by achieving at least ten consecutive business days at or above $1.00. The company said it will monitor the ADS closing price and evaluate options to regain compliance.
Scinai (Nasdaq: SCNI) executed a Second Amendment to its PinCell option agreement and submitted a revised €12 million non-dilutive FENG SMART Path application to support a €15 million integrated R&D program for PC111, a fully human anti-sFasL antibody for PV and SJS/TEN.
The amendment extends option condition deadlines to August 31, 2026 and the exercise period to September 30, 2026. A funding decision is expected in approximately three to four months.
Scinai (Nasdaq: SCNI) secured expanded Israel Innovation Authority support for its robotic aseptic fill & finish program, enabling use of the full approved grant of NIS 5 million over two years, ~66% non-dilutive. Validation is targeted for completion in Q3 2026.
The investment supports acquisition and validation of a robotic-arm system aligned with EU GMP Annex 1 and complements Scinai's recent Recipharm Israel acquisition and strategic commercial collaboration to create an integrated two-site CDMO platform.
Scinai (NASDAQ: SCNI) completed the acquisition of 100% of Recipharm Israel Ltd., adding a cGMP Yavne manufacturing site and expanding Scinai's CDMO footprint and technical scope.
The companies also signed a long-term commercial collaboration granting Scinai preferred early-stage status and access to Recipharm's global manufacturing network under predefined terms, plus a Master Quality Agreement and Tech Transfer Framework to streamline program transitions.
Scinai (Nasdaq: SCNI) announced that CEO Amir Reichman will co-lead a Manufacturers Association roundtable titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale" on January 19, 2026 at Expo Tel Aviv during HealthIL Week 2026.
The session will focus on early-stage development, CMC and analytical capabilities, clinical GMP manufacturing, access to laboratory infrastructure, and readiness for later-stage and commercial manufacturing in Israel.
Participants will include government agencies, local and international biopharma companies, CDMOs, multinationals, and investors; the discussion aims to identify structural gaps and collaboration models to strengthen Israel's biopharma manufacturing ecosystem over the next 5–10 years.